Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jan 21, 2025	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	7,117	4,882	7,694	5,659	5,765	2,591
Market Cap Growth	43.89%	-36.54%	35.96%	-1.84%	122.48%	23.18%
Enterprise Value	7,986	5,929	8,940	5,722	5,817	2,425
Last Close Price	54.80	36.96	56.90	40.21	42.71	17.73
PE Ratio	18.51	17.34	38.06	14.05	44.66	-
Forward PE	11.91	9.77	21.92	17.89	25.20	163.86
PS Ratio	7.37	5.89	11.65	12.76	21.54	13.22
PB Ratio	15.40	58.26	45.31	28.73	38.16	28.24
P/TBV Ratio	-	-	-	28.73	38.16	28.24
P/FCF Ratio	18.12	13.08	32.70	18.99	108.87	-
P/OCF Ratio	17.66	12.56	32.04	18.90	103.95	-
PEG Ratio	0.40	0.40	0.40	0.45	0.55	-
EV/Sales Ratio	8.43	7.15	13.54	12.91	21.74	12.37
EV/EBITDA Ratio	14.44	14.22	26.60	20.63	39.89	-
EV/EBIT Ratio	16.74	17.43	30.89	20.74	40.33	-
EV/FCF Ratio	20.33	15.88	37.99	19.20	109.86	-
Debt / Equity Ratio	3.39	18.27	9.07	4.47	2.66	4.46
Debt / EBITDA Ratio	2.73	3.59	4.54	3.15	2.71	-
Debt / FCF Ratio	3.91	4.10	6.55	2.95	7.59	-
Asset Turnover	0.47	0.46	0.45	0.53	0.47	0.39
Inventory Turnover	1.92	2.36	2.67	2.04	1.72	7.17
Quick Ratio	8.75	5.07	4.54	7.10	1.11	5.61
Current Ratio	10.36	6.64	5.65	7.91	1.32	6.35
Return on Equity (ROE)	111.83%	222.07%	110.23%	231.44%	106.33%	-42.41%
Return on Assets (ROA)	14.87%	11.89%	12.28%	20.48%	15.74%	-8.40%
Return on Capital (ROIC)	15.83%	12.78%	12.98%	21.16%	17.11%	-9.65%
Earnings Yield	5.51%	5.77%	2.63%	7.12%	2.24%	-2.79%
FCF Yield	5.52%	7.65%	3.06%	5.27%	0.92%	-3.45%
Buyback Yield / Dilution	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%
Total Shareholder Return	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%

Source: S&P Capital IQ. Standard template. Financial Sources.